CSL Limited has announced that it has abandoned the proposed US$3.1 billion acquisition of Talecris Biotherapeutics Holdings Corp. after the US Federal Trade Commission (FTC) sought to block the deal by commencing administrative proceedings and seeking a preliminary injunction in US District Court. The FTC's complaint alleged that the transaction would substantially lessen competition in four US markets for plasma-derivative protein therapies.